Grant support for the following independent educational activities is provided by Novartis Pharma AG, Basel, Switzerland and Boehringer Ingelheim Pharmaceuticals. Acknowledgment of support for individual activities is listed beneath each title.
Globally, approximately 30 million people suffer from heart failure. Access to education is one of the largest impediments to successful treatment of these patients. This hub aims to educate and inform treatment of this growing population of heart failure sufferers.
The Changing Landscape of SGLT2i’s: Navigating the Latest Clinical Trials
Educational grant support provided by: Boehringer Ingelheim Pharmaceuticals
Several recent large phase 3 trials for sodium-glucose co-transporter-2 (SGLT2) inhibitors have established cardiovascular benefits of SGLT2i’s among patients with T2D. These developments have generated a need for clinician education focused on the emerging science and ongoing trials that have identified expanding indications beyond the initial treatment for managing glucose in diabetes patients, especially pertaining to their potential impact on HF patients.
Patient Case Quizzes
Test your knowledge of the treatment of Heart Failure and Diabetes Mellitus with two patient case quizzes.
- Untreated HFrEF / Ischemic Cardiomyopathy in Type 2 DM – How to Optimize Medical Therapy to Improve Heart Failure Outcomes | April 10,2020
- Unrecognized HFPEF in a Type 2 DM Patient - Reducing CV & HF Risk | April 24, 2020
Learn about the relevant clinical trials, the updated indications for the SGLT2 inhibitors, and the impact on clinical practice.
- Deciphering SGLT2’s: Mechanisms of Action and Resulting Indications | May 26, 2020
- The Findings: Navigating the SGLT2s Clinical Trials | January 11, 2021
Primary Care Physician (PCP) Heart Failure | April 13, 2020
Educational grant support provided by: Novartis Pharma AG
This online learning experience allows PCPs in Latin America the opportunity to increase practical knowledge and gain valuable skills in the assessment, diagnosis, guideline-driven medical therapy, and special considerations such as acute care needs of the heart failure patient.